Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. - Wikidata - thesis-toulmin - TriplyDB

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

http://www.wikidata.org/entity/Q33585491

about

Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection)Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?CD8+ T cells in Trypanosoma cruzi infection Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease Pathogenesis of chagas' disease: parasite persistence and autoimmunity The centennial of the discovery of Chagas disease: facing the current challenges Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi.Methodological advances in drug discovery for Chagas disease.Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.Benzonidazole therapy modulates interferon-γ and M2 muscarinic receptor autoantibody responses in Trypanosoma cruzi-infected children.Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease Chagas disease and the london declaration on neglected tropical diseases.Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage.Evaluating Chagas disease progression and cure through blood-derived biomarkers: a systematic review.Polyfunctional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults.Altered distribution of peripheral blood memory B cells in humans chronically infected with Trypanosoma cruzi Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes.Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.Doxycycline and Benznidazole Reduce the Profile of Th1, Th2, and Th17 Chemokines and Chemokine Receptors in Cardiac Tissue from Chronic Trypanosoma cruzi-Infected Dogs.Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.Frequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection.Towards a paradigm shift in the treatment of chronic Chagas disease.Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.Therapy of vector-borne protozoan infections in nonendemic settings.Advances and challenges towards a vaccine against Chagas disease.Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA.Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children.Antiparasitic Treatment Induces an Improved CD8+ T Cell Response in Chronic Chagasic Patients.The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects.Vaccine-linked chemotherapy improves benznidazole efficacy for acute Chagas disease.The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.

P2860

Q24245957-7B624BB7-BEF8-4624-826F-A59484A239C8 Q26859040-DA994FE6-4FF1-4C51-8A47-CA08F7F3F212 Q28081766-29159A71-F9B7-487D-9CA5-8170714E74FF Q28083346-87827235-67B7-4F18-8FCB-4CC17985AACB Q28742827-C713E96E-B735-4998-9D84-613BBFD742A4 Q33627688-E39FA83E-FEBE-4399-B58A-300C6E19B434 Q33719577-1C49458D-62D9-4E63-8444-78E905A3CFA4 Q33945347-C7EB4154-D6AD-46EC-879A-51CFECC1750D Q33975717-FC36B56B-54BF-4A82-AC1E-627DC53D18AA Q34016698-3D17F80E-EB75-454D-813D-3EBAB7764375 Q34069688-F229F57A-CC4A-47EC-A88A-22FF7C332D7F Q34264559-0F3CAE87-86E8-45D7-94FF-BB4145C14B3F Q34315066-9E9A5AEC-9B66-47B4-99D9-07C40F4E3721 Q34584940-9192ABAC-9D1D-4712-BB49-7DB8CFFD2039 Q34707808-05060056-5A2B-4289-AF01-D97C1C51DF3C Q34992879-12769568-E624-40EF-808B-817118F1E3AC Q35071204-007CB5A2-AF5E-4C8D-AD2F-E2D1DA01E986 Q35222938-E9340CF4-1DA4-47B1-9FBA-487F9E92BA04 Q35810790-FE774F8B-4961-427F-8320-6462F3830DB7 Q36256258-1053DD0B-4B5B-472C-A5E7-2100AE71ED74 Q36526649-CCA9CCC6-07D4-4AB6-AAF5-387833531EBB Q37256759-233CDDC6-EA9B-4F72-A340-00C077669B84 Q37286061-4B7E2294-964E-497C-9F9E-2E124A51181D Q37395315-9367931B-55F5-4DC7-A15A-DA51A4060678 Q37535347-56823F38-9217-4222-9E97-1D4ECF83F066 Q37544885-0805D8FE-335E-4879-BB5C-D867220025E8 Q37717875-B36EEBB8-632A-4E79-9CDF-CCB7E1051DD0 Q37879203-A05C2861-5B45-4FC0-B767-1C3304ABEE1B Q37952062-273839DC-D064-4EC8-B7F3-7F9B78F3AE74 Q37998091-CC6688F7-4AA9-40C8-B454-11FA598A34F0 Q38195336-860DE34A-A1CE-4D15-8CD4-DE3866C295E5 Q38256874-839AD760-2A6C-4FBB-B0BC-E23A72FDD8C4 Q38871286-087FAA03-F361-4790-9824-4CC77655901A Q38927054-86D0EA18-F45E-4FA4-AEAA-7BCC6C696E01 Q39372756-F5DA8CB6-DA9B-4111-9B8C-4EEF42052DEE Q40254337-459CC559-43AD-4B49-8F8F-972A86C00B0D Q40309242-F2A712DE-F536-4ED3-93B4-D8769AE4D5AF Q41665227-520A038E-1950-47EC-B02E-9358D2FC6A1E Q47557112-B4650E6B-2E4F-42A9-814F-E07A5E0760EC Q48243287-E49C405B-698E-4198-9BA6-358F074A45B5

P2860

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

http://www.wikidata.org/entity/Q33585491

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@ast

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@en

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@nl

type

label

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@ast

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@en

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@nl

prefLabel

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@ast

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@en

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@nl

P1433

Q33585491-C3312F32-1784-4D31-AD98-7DBF0A929E9A

P1476

Q33585491-907ECD78-DE18-419E-9B4F-82D593E3FED4

P2093

Q33585491-01466A6E-157E-47CB-A3D5-EFD51D18A469

Q33585491-271F8F97-10FE-42FC-A077-1D6E11E0928A

Q33585491-404B55D0-25A1-49B0-95A8-88581580785C

Q33585491-470CEA70-36A4-4C0E-A7F7-7149A9418F02

Q33585491-4A7AC18A-2129-4E02-9291-BC3D7D00BCE2

Q33585491-6746456A-3646-47E4-B7C6-77130F81151C

Q33585491-986DB2A7-7DD3-439F-8B09-E73CC78E6301

Q33585491-B14DE92D-FA9A-4EEE-8A59-444E8664E3E4

Q33585491-DB917A49-D187-4536-97C3-1CEB63210C59

Q33585491-F4188F59-83AC-4AC2-AE36-BC0AA67EC7E3

P2860

Q33585491-01770BFF-6168-4B18-B875-7AF3B92EFE3C

Q33585491-090C8761-C847-4281-B756-0DF3972DF228

Q33585491-124E20C4-9D00-4BE5-940B-25C53FD61B32

Q33585491-18A37141-37F5-415E-AE63-E33F023C145B

Q33585491-1B04FE67-30B8-4B9A-B70A-A6CE69959CF1

Q33585491-2F79C7B7-B28D-4F1E-AC17-CDF3D49A6982

Q33585491-3316F35D-BD4B-4A60-B1F1-551571439E06

Q33585491-3646601E-DAA1-4DD8-B372-1E656ED391FD

Q33585491-383659E9-C1ED-4774-BCA8-BA268522FDEB

Q33585491-3DCA9488-F4AA-444E-9AE7-01F83F942BD0

P304

Q33585491-8681125C-A920-4501-B70A-CB5DF4CED72B

P31

Q33585491-ACFF9122-080F-434B-B143-785CEF56C719

P356

Q33585491-B5891B51-4BD3-4AA0-9E93-E6BB59F76204

P407

Q33585491-A6142111-3138-4F24-B13B-431D7BC3224F

P433

Q33585491-09B0379D-4A52-4F97-AFEC-FFB3D067BA78

P478

Q33585491-A8C7A8C4-A7A6-4BFA-A1D6-AEBB85F28BF3

P50

Q33585491-294DE2E8-0A2A-4FCB-950E-92059EB71756

P5008

Q33585491-E4686BC4-AB84-458B-A193-BEB8DB75C108

P577

Q33585491-A1B3BB03-97D9-4312-8F23-A415FADF0F9D

P5875

Q33585491-C434049B-9E94-4C3A-A6F8-B5080398831F

P698

Q33585491-0DE52864-0760-49EE-AB44-8AC133F65588

P921

Q33585491-2A28E73E-FEDF-4C28-9B0A-45E62E0D0424

P932

Q33585491-5BF7E7C1-395F-4E13-B3F3-A53E46A64F9E

P356

P1433

Clinical Infectious Diseases

P1476

Changes in Trypanosoma cruzi-s ...... markers of treatment efficacy.

@en

P2093

Alejandro Armenti

http://www.w3.org/2001/XMLSchema#string

Bruno Lococo

http://www.w3.org/2001/XMLSchema#string

Damián Pérez Mazliah

http://www.w3.org/2001/XMLSchema#string

Graciela Bertocchi

http://www.w3.org/2001/XMLSchema#string

Gretchen Cooley

http://www.w3.org/2001/XMLSchema#string

María C Albareda

http://www.w3.org/2001/XMLSchema#string

María G Alvarez

http://www.w3.org/2001/XMLSchema#string

Miriam Postan

http://www.w3.org/2001/XMLSchema#string

Rodolfo Viotti

http://www.w3.org/2001/XMLSchema#string

Susana A Laucella

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations

Viral immune evasion due to persistence of activated T cells without effector function

Sustained Dysfunction of Antiviral CD8+ T Lymphocytes after Infection with Hepatitis C Virus

Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression

High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection

Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment.

The challenges of Chagas Disease-- grim outlook or glimmer of hope.

HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease.

A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.

Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

P304

1675-1684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/648072

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Rick L. Tarleton

P5008

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38056315

http://www.w3.org/2001/XMLSchema#string

P698

19877967

http://www.w3.org/2001/XMLSchema#string

P921

Trypanosoma cruzi

P932

2805187

http://www.w3.org/2001/XMLSchema#string